Collectively, our data indicate that YTHDF2 may play an essential role in mitigating synovial fibroblast inflammation and bone injury in the pathogenesis of RA by reducing the mRNA stability of IL‐6R, providing a theoretical evidence for exploring novel therapeutic approaches for RA. This evidence concerns the gene YTHDF2 and rheumatoid arthritis.